About NuCana plc - American Depositary Shares (NCNA)
Nucana Plc is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment. The company utilizes its proprietary nucleoside chemistry platform to design and create next-generation nucleoside analogs that target various cancer types. Nucana aims to address the limitations of existing cancer therapies by developing treatments that can enhance efficacy and reduce toxicity, ultimately improving patient outcomes. Through its research and clinical trials, the company is dedicated to advancing new medicines that offer hope to patients battling challenging malignancies. Read More
In today’s market, investors are scanning for deeply undervalued stocks with disruptive technology, breakthrough clinical assets, and high-impact news catalysts. Several oversold equities trading under $1 have emerged with notable developments, drawing algorithmic attention across trading platforms, financial news networks, and Google-indexed search results.
Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025
Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival Following Treatment with NUC-3373 plus Pembrolizumab
EDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering NUC-7738’s composition of matter. This patent (US12,054,510) is expected to serve as a key component of the intellectual property protection for NUC-7738, which currently consists of over 80 issued patents worldwide. NUC-7738 is a novel anti-cancer agent currently in a Phase 2 clinical study in combination with pembrolizumab in PD-1 inhibitor resistant melanoma patients, for which NuCana presented encouraging data at the ESMO Congress 2024 earlier this month.
NuCana presented final data from a Phase 2 study at ESMO Congress, showing NUC-7738 combined with Keytruda achieved a 75% disease control rate in metastatic melanoma patients resistant to prior PD-1 inhibitors.
Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety Profile
NuCana will discontinue the NuTide:323 study after an initial analysis recommended by the Steering Committee, as the combination treatment was unlikely to achieve superior Progression-Free Survival compared to the control arm.
